The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 57, Issue 5, 2016, Pages 1174-1181

  Wang, Wei ^a   Gao, Li ^a   Li, Yan ^a   Li, Zhen Ling ^a   Gong, Ming ^a   Huang, Fan Zhou ^a   Chen, Yan Rong ^a   Zhang, Chun Xia ^a   Gao, Ya Yue ^a   Ma, Yi Gai ^a  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

B cell acute lymphoblastic leukemia; flow cytometry; minimal residual disease

Indexed keywords

5' NUCLEOTIDASE; CD20 ANTIGEN; CD34 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; B LYMPHOCYTE; BONE MARROW; CANCER CHEMOTHERAPY; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGED; GENE EXPRESSION; GENETICS; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SENSITIVITY AND SPECIFICITY;

5'-NUCLEOTIDASE; ADULT; AGED; ANTIGENS, CD; BIOMARKERS, TUMOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SENSITIVITY AND SPECIFICITY;

EID: 84945207084     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1070153     Document Type: Article

References (24)

1. Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009; 23: 1083-1098, vii.
2. Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113: 4153-4162.
3. Bruggemann M, Raff T, Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood 2012; 120: 4470-4481.
4. Meleshko AN, Savva NN, Fedasenka UU, et al. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols. Leuk Res 2011; 35: 1312-1320.
5. Faderl S, O'Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 2010; 116: 1165-1176.
6. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
7. Bruggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24: 521-535.
8. Weng XQ, Shen Y, Sheng Y, et al. Prognostic significance of monitoring leukemia-Associated immunophenotypes by eight-color flow cytometry in adult B-Acute lymphoblastic leukemia. Blood Cancer J 2013; 3: e133.
9. Fossat C, Roussel M, Arnoux I, et al. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: a French multicenter study. Cytometry B Clin Cytom 2015; 88: 21-29.
10. Obro NF, Ryder LP, Madsen HO, et al. Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods. Haematologica 2012; 97: 137-141.
11. McKenna RW, Washington LT, Aquino DB, et al. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001; 98: 2498-2507.
12. Coustan-Smith E, Song G, Clark C, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011; 117: 6267-6276.
13. Borowitz MJ, Chan JKC. Blymphoblastic leukaemia/lymphoma, not otherwise specified. lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities. In: Swerdlow. SH CE, Harris NL, Jaffe ES, etal., editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: The International Agency for Research on Cancer (IARC); 2008. p 168-175.
14. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-1786.
15. Babusikova O, Zeleznikova T, Kirschnerova G, et al. Hematogones in acute leukemia during and after therapy. Leuk Lymphoma 2008; 49: 1935-1944.
16. Loken MR, Wells DA. Normal antigen expression in hematopoiesis basis for interpreting leukemia phenotypes. In: Stewart CC, Nicholson JKA., editors. Immunophenotyping. New York: Wiley-Liss; 2000. p 133-160.
17. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-A Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
18. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317.
19. Solly F, Angelot F, Garand R, et al. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry. Cytometry A 2012; 81: 17-24.
20. DiGiuseppe JA, Fuller SG, Borowitz MJ. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection. Cytometry B Clin Cytom 2009; 76: 150-155.
21. Muzzafar T, Medeiros LJ, Wang SA, et al. Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry. Am J Clin Pathol 2009; 132: 692-698.
22. Diaz D, Prieto A, Barcenilla H, et al. Loss of lineage antigens is a common feature of apoptotic lymphocytes. J Leukoc Biol 2004; 76: 609-615.
23. van der Sluijs-Gelling AJ, van der Velden VH, Roeffen ET, et al. Immunophenotypic modulation in childhood precursor-B-ALL can be mimicked in vitro and is related to the induction of cell death. Leukemia 2005; 19: 1845-1847.
24. Dworzak MN, Gaipa G, Schumich A, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. Cytometry B Clin Cytom 2010; 78: 147-153.